You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.
The companies will use HTG EdgeSeq technology to develop NGS-based gene expression profiling assays to support a pharma company's therapeutic development.
This finding has the potential to expand the current utility of the panel to identify an important subgroup of people who would benefit from less treatment, the firm said.
New data now suggests that evaluating PD-L2 levels might better predict response to PD-1 targeting immune-oncology drugs than current tests that only measure PD-L1.
RNA sequencing of patient-derived fibroblasts was able to provide 10 percent of patients with a diagnosis after whole-exome sequencing had failed.
The Medicare contractor proposed coverage for several cancer assays, but would not cover molecular respiratory virus assays or a test for inflammatory bowel disease.
The collaboration will streamline patient sample analysis to determine whether they should be included in clinical trials for molecularly targeted treatment.
The company published a new study of average- and high-risk patients showing that the test better predicted metastasis in patients treated with radiation and hormonal therapy.
The firm expects full-year revenue growth of up to 39 percent, but fell short of prior guidance for the year.
The firm said that it delivered more than 29,990 test results in the third quarter of 2016 compared to 27,820 results delivered in Q3 2015.
The results showed overall high concordance between test results and whether patients received chemotherapy, with some relevant exceptions.